Lilly’s retatrutide beats Ozempic in a diabetes trial (not approved) Lilly announced that its investigational once-weekly drug retatrutide, tested against Ozempic 2 mg in 1,298 adults with type 2 diabetes, led to average weight loss of 19.5% (9 mg) and 20.9% (12 mg) at 80 weeks, versus 9.4% on Ozempic. A1C fell 2.2 points versus
